glp 1 microdose tirzepatide Microdosing Program Microdosed Tirzepatide

At 12 months, weight loss persisted at around 4%, with variability between agents, most notably liraglutide

CagriSema: This Novo Nordisk combination is a fixed-dose co-formulation of the GLP-1 agonist semaglutide and the long-acting amylin analogue cagrilintide

It can reduce weight by up to 24% in only 48 weeks, compared to tirzepatide, which reduced weight by 20.9% after 72 weeks

Consultings Executive Insights will explore how payers should strategize their approach to glucagon-like peptide-1 agonists (GLP-1s) as they weigh rising consumer demand and increasing pharma supply with recognition of longer-term return on investment (ROI) opportunity

Nothing is added later

Available at: Accessed February 2nd, 2024